Senseonics, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, announced that it has raised an additional $20 million of private equity financing. Senseonics also announced that Mirasol Panlilio, formerly of Abbott Diabetes Care and LifeScan, has joined the company as Vice President of Global Sales and Marketing.
Current investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other strategic partners all participated in the financing round. Senseonics intends to use the proceeds to continue its product development initiatives including completing pivotal trials in Europe, obtaining CE mark, and initiating IDE trials in the United States. “We’re very happy of the continued support from our investors as we near the completion of the product development efforts for our first generation long-term CGM system, “ said Tim Goodnow, CEO and President. Senseonics has recently begun its European pivotal trials and expect to complete site initiation of all seven European sites before the end of summer.